Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer’s biosimilar to J&J’s Remicade; Novartis to downsize generics business
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
As digital-health funding increases, here’s how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.
Get the most out of
Register for free and enjoy unlimited access to: